Floatz logo

ETOPOSIDE

Adult Acute Myelomonocytic Leukemia (M4)

Stanford UniversitySmall moleculePhase 3Dormant
BBB
79/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Adult Acute Myelomonocytic Leukemia (M4) cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
University of Alberta
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
ECOG-ACRIN Cancer Research Group
Phase 3BBB
Idarubicine
University of Alberta
Phase 3BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BBB

View all 50 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →